Global biotech company I-Mab ( NASDAQ: IMAB ) said that Board of Directors appointed Mr. Wei Fu as the chairman of the Board of Directors. He succeeds Dr.
Pamela M. Klein, who steps down from I-Mab's ( IMAB ) Board of Directors and the interim chairperson position. In addition, Mr.
Raj Kannan intends to leave his role as CEO and as a member of the company's Board of Directors, effective July 15, 2024. Mr. Kannan will stay as an advisor of the company until July 31, 2024, to assist with the transition.
Dr. Sean Xi-Yong Fu has assumed the role of interim CEO and a member of the Board of Directors, effective July 15, 2024. More on I-Mab Biopharma Seeking Alpha’s Quant Rating on I-Mab Biopharma Historical earnings data for I-Mab Biopharma Financial information for I-Mab Biopharma.
